The Lancet Rheumatology is an independent journal committed to publishing content relevant to rheumatology specialists worldwide, with a focus on studies that advance clinical practice, challenge the status quo, and advocate change in health policy. The journal publishes clinical research (with a focus on clinical trials), expert reviews, and provocative comment and opinion relating to the diagnosis and classification, management, and prevention of rheumatic diseases, including arthritic, musculoskeletal, and connective tissue diseases, as well as disorders of the immune system. The journal also publishes high-quality human translational studies that are supported by robust clinical data, with priority given to studies that identify potential new therapeutic targets, advance efforts toward precision medicine, or have the potential to directly inform future clinical trials.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7,000 employees in over 70 offices worldwide publish more than 2,500 peer-reviewed journals and more than 11,000 online books. In 2010 Elsevier launched SciVerse, an innovative platform for electronic solutions such as ScienceDirect, Scopus, Scirus, and SciTopics enabling more efficient search and discovery for our users. SciVerse combines peer-reviewed content with product enhancing applications to facilitate collaboration, reward innovation and to accelerate science.